Monitoring of the immune responses following mogamulizumab containing treatment in patients with adult T-cell leukemia-lymphoma (MIMOGA study)
Not Applicable
- Conditions
- Adult T-cell leukemia-lymphoma
- Registration Number
- JPRN-UMIN000008696
- Lead Sponsor
- agoya City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Subjects with a history of receiving mogamulizumab 2) Subjects with a history of receiving allogeneic hematopoietic stem cell transplantation. 3) Subjects who are determined to have any serious difficulties for 6 months immune monitoring after their enrollment by the physician. 4) Subjects who are pregnant, of childbearing potential, or lactating. 5) Subjects who are determined to be unsuitable for enrolled in the present study by the physician.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the immune responses such as the number of CD4/CD8 positive T cells, NK cells, B cells, Treg cells, and HTLV-1 specific cytotoxic T cells in blood following mogamulizumab containing treatment in the ATL patients.
- Secondary Outcome Measures
Name Time Method Efficacy of mogamulizumab containing treatment Adverse events of mogamulizumab containing treatment Overall survival